Detail akcie Becton Dickinson online

Business Summary: Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others. The Company's BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, and pharmaceutical systems. The Company's BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
Financial Summary: BRIEF: For the six months ended 31 March 2024, Becton Dickinson and Co revenues increased 4% to $9.75B. Net income applicable to common stockholders decreased 11% to $818M. Revenues reflect Interventional segment increase of 7% to $2.48B, Medical segment increase of 4% to $4.68B, Life Sciences segment increase of 1% to $2.59B, United States segment increase of 4% to $5.66B. Dividend per share increased from $1.82 to $1.90.